Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations, or exhibits a genetic profile, listed in Tables 1-5, and/or FIGS. 1-3.

Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.

Abstract: Recombinant carbonic anhydrase variants having improved solubility and/or thermostability for enzyme-enhanced CO2 capture are provided. Host cells, methods, and processes relating to same are also provided.

Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. 19-22.

Abstract: Methods for enzyme-enhanced CO2 capture include contacting a CO2-containing gas with an aqueous absorption solution at process conditions—such as high temperature, high pH, and/or using carbonate-based solutions—in the presence of Thermovibrio ammonificans carbonic anhydrase (TACA) or functional derivative thereof for catalyzing the hydration reaction of CO2 into bicarbonate and hydrogen ions and/or catalyzing the desorption reaction to produce a CO2 gas. The TACA may be provided to flow with the solution to cycle through a CO2 capture system that includes an absorber and a stripper.

Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Abstract: The present description relates to recombinant or engineered carbonic anhydrase polypeptides, variants, and functional derivatives thereof, having improved properties that make them advantageous for use in CO2 capture operations (e.g., CO2 capture solvents, alkaline pH, and/or elevated temperatures), as well as polynucleotides and vectors encoding same. The present description also relates to methods, processes and systems for CO2 capture which make use of the recombinant or engineered carbonic anhydrase polypeptides, variants, and functional derivatives thereof.

Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The present description relates to recombinant or engineered carbonic anhydrase polypeptides, variants, and functional derivatives thereof, having improved properties that make them advantageous for use in CO2 capture operations (e.g., CO2 capture solvents, alkaline pH, and/or elevated temperatures), as well as polynucleotides and vectors encoding same. The present description also relates to methods, processes and systems for CO2 capture which make use of the recombinant or engineered carbonic anhydrase polypeptides, variants, and functional derivatives thereof.

Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Abstract: Sulfurihydrogenibium sp. carbonic anhydrase (SspCA) or mutants thereof catalyze a hydration reaction of CO2 into bicarbonate and hydrogen ions or a desorption reaction to produce a CO2 gas. Sulfurihydrogenibium sp. carbonic anhydrase (SspCA) having improved thermostability in the presence of carbonate ions as compared to in the absence of carbonate ions are useful in the capture of CO2 from a CO2-containing gas.

Abstract: Methods for enzyme-enhanced CO2 capture include contacting a CO2-containing gas with an aqueous absorption solution at process conditions—such as high temperature, high pH, and/or using carbonate-based solutions—in the presence of Thermovibrio ammonificans carbonic anhydrase (TACA) or functional derivative thereof for catalyzing the hydration reaction of CO2 into bicarbonate and hydrogen ions and/or catalyzing the desorption reaction to produce a CO2 gas. The TACA may be provided to flow with the solution to cycle through a CO2 capture system that includes an absorber and a stripper.

Abstract: Use of Sulfurihydrogenibium sp. carbonic anhydrase (SspCA) or mutants thereof for catalyzing the hydration reaction of CO2 into bicarbonate and hydrogen ions or catalyzing the desorption reaction to produce a CO2 gas is provided.

Abstract: The present disclosure relates to a combination of an inhibitor of human histone methyltransferase DOT1L, such as EPZ-5676 or salts thereof, and one or more DNMT inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.